The effect of p-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi

Clinical Nuclear Medicine

Volumn 25, Issue 1, 2000, Pages 20-23

  Kabasakal, Levent ^a   Halaĉ, Metin ^a   Nisli, Cavit ^a   Oguz, Oya ^a   Önsel, Ĉetin ^a   Ĉivi, Gonca ^a   Uslu, Ilhami ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cyclosporine A; Multidrug Resistance; P Glycoprotein; Tc 99m MIBI

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN A; GLYCOPROTEIN P; LIVER ENZYME; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ALOPECIA; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG UPTAKE; FEMALE; HEART; HUMAN; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIVER; MALE; MULTIDRUG RESISTANCE;

ALOPECIA; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; FEMALE; HEART; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; MALE; MYOCARDIUM; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0033971353     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200001000-00005     Document Type: Article

References (24)

1. Biedler JL, Riehm H, Peterson RHF, Spengler BA: Membrane mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 55:671, 1975.
2. Ling V, Thomson LH: Reduced permeability in CHO cells as a mechanism of resistance to cochisine. J Cell Physiol 83:103, 1974.
3. Chan HSL, DeBoer G, Thorner PS, et al: Multidrug resistance: Clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin North Am 8:383, 1994.
4. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553, 1993.
5. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI: Reversal of multi-drug resistance to cancer chemotherapy Cancer 72:3484, 1993.
6. Caner B, Kitapci M, Aras T, et al: Increased accumulation of hexakis (2-methoxy isobutyl isonitrile) technetium (I) in osteosarcoma and its metastatic lymph nodes. J Nucl Med 32:1977, 1991.
7. Özcan Z, Ĉalkavur Ŝ, Erenel G, et al: Clinical experience with Tc-99m-MIBI scintigraphy in childhood neoplasms. Tur J Nucl Med 6:283, 1997.
8. Kapucu LÖ, Akyüz C, Ǒguz A, et al: Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 38:243, 1997.
9. Piwnica-Worms D, Chiu ML, Budding J, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organothechnetium complex. Cancer Res 53:977, 1993.
10. Kabasakal l, Özker K, Hayward M, et al: Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med 23:568, 1996.
11. Kabasakal L-, Halaĉ M, Niŝli C, et al. Monitoring multidrug resistant p-glycoprotein function with Tc-99m-MIBI: The effect of cyclosporine-A. Tur J Nucl Med 7:41, 1998.
12. Derebek E, Deǧirmenci B: Multidrug resistance in chemotherapy: New perspective for nuclear medicine. Tur J Nucl Med 6:303, 1997.
13. Hitchins RN, Harman DH, Davey RA, Bell DR: Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur J Cancer Clin Oncol 24:449, 1988.
14. Muller M, Jansen PL: Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285, 1997.
15. Fricker G, Drewe J, Miller D: Relevance of P-glycoprotein for the transport of cyclosporine A across intestine, liver and kidney. Hepatology 28:13, 1997.
16. Marie JP, Bastie JN, Coloma F, et al: A phase I-II trial of cyclosporine with etoposide and mitoxantrone in advanced acute leukemia. Proc Am Soc Clin Oncol 11:275, 1992.
17. Yahanda AM, Adler KM, Fisher GA, et al: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance J Clin Oncol 10:1624, 1992.
18. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635, 1992.
19. Roepe PD: The role of the MDR protein in altered drug translocation across tumor cell membranes. Bichim Biophys Acta 1241:385, 1995.
20. Hoffman MM, Wei LY, Roepe P: Are altered pHi and membrane potential in hu MDR1 transfectants sufficient to cause MDR protein-mediated multidrug resistance. J Gen Physiol 108:295, 1996.
21. Piwnica-Worms D, Kronauge JF, Chiu ML: Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium (I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 82:1826, 1990.
22. Kostakoǧlu L, Elahi N, Kiratli P, et al: Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uphake in malignant tumors. J Nucl Med 38:1003, 1997.
23. Bhatnagar A, Vezza, PR, Bryan JA, Atkins FB, Ziessman HA: Technetium-99m-sestamibi parathyroid scintigraphy: Effect of p-glycoprotein, histology and tumor size on detectability. J Nucl Med 39:1617, 1998.
24. Chen CC, Meadows B, Regis J, et al: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Can Res 3:545, 1997.